PDF herunterladen
Thromb Haemost 1977; 38(04): 0831-0849
DOI: 10.1055/s-0038-1651902
Original Article
Schattauer GmbH

The Intravascular Generation of Fibrinogen Derivatives and the Blood Vessel Wall in Venous Thrombosis and Disseminated Intravascular Coagulation

Gwendolyn J. Stewart
1   SCOR Center for Thrombosis Research, Temple U. H. S. C., Philadelphia, Pa. 19140, U.S.A.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Juli 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Both deep venous thrombosis and DIC are intermediate mechanisms of disease – both are a consequence of the deposition of fibrin-rich material in blood vessels some distance from the primary site of tissue destruction. The great difference in the sites of fibrin deposition may depend on the extent and site of activation of the clotting mechanism. DIC likely occurs in the fluid phase of the blood as a consequence of massive fibrin formation while thrombosis results from limited fibrin formation at the interface between blood and vessel wall. Leukocytes may be essential for attaching thrombi to the vessel wall in many places.

 

  • References

  • 1 Alkjaersig N, Abe T, Seegers W. H. 1955; Purification and quantitative determination of platelet factor 3. American Journal of Physiology 181: 304.
    PubMedGoogle Scholar
  • 2 Altman R, Hemker H. C. 1967; Contact activation in the extrinsic blood clotting system. Thrombosis et Diathesis Haemorrhagica 18: 525.
    PubMedGoogle Scholar
  • 3 Amundsen M. A, Spittell J. A, Thompson J. A, Owen Jr. C. A. 1963; Hypercoagulability associated with malignant disease and with the postoperative state. Evidence for elevated levels of antihomophilic globulin. Annals of Internal Medicine 58: 608.
    CrossrefPubMedGoogle Scholar
  • 4 Astrup T. 1969. Relation between fibrin formation and fibrinolysis. In: Thrombosis. (eds.) Sherry S, Brinkhous K. M, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C; 609.
    Google Scholar
  • 5 Austen K. F. 1974; Hageman factor-dependent coagulation, fibrinolysis and kinin generation. Transplantation Proceedings 6: 39.
    PubMedGoogle Scholar
  • 6 Bach C, Lewis G. P. 1974; Lymph flow and lymph protein concentration in the skin and muscle of the rabbit hind limb. Journal of Physiology (London) 235: 477.
    PubMedGoogle Scholar
  • 7 Bagdasarian A, Lahiri B, Colman R. W. 1973; Origin of the high molecular weight activations of human plasmin kallikrein. Journal of Biological Chemistry 248: 7742.
    PubMedGoogle Scholar
  • 8 Banerjee R. N, Sahni A. L, Kumar V, Arya M. 1974; Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thrombosis et Diathesis Haemorrhagica 31: 339.
    PubMedGoogle Scholar
  • 9 Baumann K, Straub P. W. 1969; Congenital deficiency of Hageman factor (clotting, factor XII). Report on the first two families found in Switzerland. Helvetica Medica Acta 34: 313.
    PubMedGoogle Scholar
  • 10 Bell W. R, Regoecz E. 1970; Isotopic studies of therapeutic anticoagulation with a coagulating enzyme. Journal of Clinical Investigation 49: 1872.
    CrossrefPubMedGoogle Scholar
  • 11 Bouma B. N, Griffin J. H. 1977; Human prekallikrein (plasminogen proactivation): Purification, characterization and activation by activated factor XII. Thrombosis and Haemostasis 38: 136.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Boyden S. 1962; The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. Journal of Experimental Medicine 115: 453.
    CrossrefPubMedGoogle Scholar
  • 13 Boyles S, Lewis G. P, Westcott B. 1970; Changes in the composition of hind limb lymph after chemical injury. British Journal of Pharmacology 39: 798.
    CrossrefPubMedGoogle Scholar
  • 14 Brakman P. 1966; The fibrinolytic system in human blood during pregnancy. American Journal of Obstetrics and Gynecology 94: 14.
    CrossrefPubMedGoogle Scholar
  • 15 Brakman P, Albrechtsen O. K, Astrep T. 1967; Blood coagulation, fibrinolysis and contraceptive hormones. Journal of American Medical Association 199: 69.
    CrossrefPubMedGoogle Scholar
  • 16 Brinkhous K. M, Smith H. P, Warner E. D, Seegers W. H. 1939; Inhibition of blood clotting: unidentified substance which acts in conjunction with heparin to prevent conversion of prothrombin into thrombin. American Journal of Physiology 125: 683.
    PubMedGoogle Scholar
  • 17 Buckley I. K, Ryan G. B. 1969; Increased vascular permeability: The effect of histamine and serotonin on rat mesenteric blood vessels in vivo. American Journal of Pathology 55: 329.
    PubMedGoogle Scholar
  • 18 Burrowes C. E, Habal F. M, Movat H. Z. 1975; The inhibition of human plasma kallikrein by antithrombin III. Thrombosis Research 7: 175.
    CrossrefPubMedGoogle Scholar
  • 19 Burrowes C. E, Movat H. Z, Soltay H. J. 1971; The kinin system of human plasma VI. The action of plasmin. Proceedings of the Society for Experimental Biology and Medicine 138: 959.
    PubMedGoogle Scholar
  • 20 Bywaters E. G. L, Beall D. 1941; Crush injuries with impairment of renal function. British Medical Journal 1: 425.
    CrossrefPubMedGoogle Scholar
  • 21 Cash J. D. 1975; Short-term enhancement of plasminogen activator in vivo by drugs. Thrombosis et Diathesis Haemorrhagica 34: 648.
    PubMedGoogle Scholar
  • 22 Cash J. D, McGill R. C. 1969; Fibrinolytic response to moderate exercise in young male diabetics and non-diabetics. Journal of Clinical Pathology 22: 32.
    PubMedGoogle Scholar
  • 23 Clarke R. L, Orandi A, Cliffton E. E. 1960; Induction of fibrinolysis by venous obstruction. Angiology 11: 367.
    CrossrefPubMedGoogle Scholar
  • 24 Cochrane C. G, Revak S. D, Akin B. S, Wuepper K. D. 1972. The structural characteristics and activation of Hageman factor. In: Inflammation, Mechanism and Control. (eds.) Lepow I. H, Ward P. A. Academic Press; New York and London: 119.
    Google Scholar
  • 25 Cochrane C. G, Revak S. D, Wuepper K. D. 1973; Activation of Hageman factor in solid and fluid phases. Journal of Experimental Medicine 138: 1564.
    CrossrefPubMedGoogle Scholar
  • 26 Cochrane C. G, Wuepper K. D. 1971; First component of the kinin – forming system in human and rabbit plasma: Its relationship to clotting factor XII (Hageman factor). Journal of Experimental Medicine 134: 989.
    PubMedGoogle Scholar
  • 27 Collen D, Decock F, Verstraete M. 1975; Immunochemical distinction between antiplasmin and α1-antitrypsin. Thrombosis Research 7: 245.
    CrossrefPubMedGoogle Scholar
  • 28 Collins G. J, Haymann R. L, Zaitchuk R. 1975; Hypercoagulability in patients with peripheral vascular disease. American Journal of Surgery 130: 2.
    CrossrefPubMedGoogle Scholar
  • 29 Colman R. W. 1969; Activation of plasminogen by human plasma kallikrein. Biochemical and Biophysical Research Communication 35: 273.
    CrossrefPubMedGoogle Scholar
  • 30 Colman R. W. 1974; Formation of human plasma kinin. New England Journal of Medicine 291: 509.
    CrossrefPubMedGoogle Scholar
  • 31 Colman R. W, Bagdasarim A, Talamo R. C, Scott C. F, Seavey M, Guimaraes J. A, Pierce J. V, Kaplan A. P. 1975; Wilhams trait. Human kinogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Journal of Clinical Investigation 56: 1650.
    CrossrefPubMedGoogle Scholar
  • 32 Cooke E. D, Bowcock S. A, Plicher M. F, Ibbotson R. M, Gordon Y. B, Sola C. M, Chard T, Ainsworth M. E. 1975; Serum fibrin(ogen) degradation products in diagnosis of deep vein thrombosis and pulmonary embolism after hip surgery. Lancet July 12: 51.
    PubMedGoogle Scholar
  • 33 Cooper H. A, Bowie E. J. W, Owen Jr. C. A. 1973; Chronic induced intravascular coagulation in dogs. American Journal of Physiology 225: 1355.
    PubMedGoogle Scholar
  • 34 Cooperberg A. A, Teitelbaum J. I. 1961; The concentration of antihemophilic globulin (AHG) in patients with coronary artery disease. Annals of Internal Medicine 54: 899.
    CrossrefPubMedGoogle Scholar
  • 35 Cope O, Moore F. D. 1943; The study of capillary permeability in experimental burns and burn shock using radioactive dyes in blood and lymph. Journal of Clinical Investigation 23: 241.
    PubMedGoogle Scholar
  • 36 Davidson E, Tomlin S. 1963; The levels of the plasma coagulation factors after trauma and childbirth. Journal of Clinical Pathology 16: 112.
    CrossrefPubMedGoogle Scholar
  • 37 Dunn J. S, Gillepsie M, Niven J. S. F. 1941; Renal lesions in two cases of crush syndrome. Lancet 241: 549.
    PubMedGoogle Scholar
  • 38 Flute P. T, Kakkar V. V, Renney J. T. G, Nicolaides A. N. The blood and venous thromboembolism. In: Thromboembolism: Diagnosis and Treatment. (eds.) Kakkar V. V, Joucher A. J. The Wilhams and Wilkins Co.; Baltimore, Maryland: 1972: 2-12.
    Google Scholar
  • 39 Forbus W. D. 1952. In: Reaction to Injury. The Wilhams and Wilkins Co.; Baltimore, Maryland: 61.
    Google Scholar
  • 40 Fulton L. D, Page E. W. 1948; Nature of the refractory state following sublethal dose of human placental thromboplastin. Proceedings of the Society for Experimental Biology and Medicine 68: 594.
    PubMedGoogle Scholar
  • 41 Gallus A. S, Hirsh J, Gent M. 1973; Relevance of preoperative and postoperative blood tests to postoperative leg — vein thrombosis. Lancet II: 325.
    PubMedGoogle Scholar
  • 42 Gigli I, Mason J. W, Colman R. W, Austen K. F. Interaction of plasma kallikrein with CT inhibitor. Journal of Immunology 104: 574.
    PubMedGoogle Scholar
  • 43 Gjønnaess H. 1972; Cold – promoted activation of factor VII. Relation to the coagulation system. Thrombosis et Diathesis Haemorrhagica 28: 194.
    PubMedGoogle Scholar
  • 44 Godal H. C, Madsen K, Weissen-Meyer R. 1962; Thromboembolism in patients with total proconvertin (factor VII) deficiency. Acta Medica 171: 325.
    PubMedGoogle Scholar
  • 45 Goodnight Jr. S. H. 1974; Bleeding and intravascular clotting in malignancy: a review. Annals of New York Academy of Science 230: 271.
    CrossrefPubMedGoogle Scholar
  • 46 Goodnight S. H, Kenoyer G, Rapaport S. I, Patch M. J, Lee J. A, Kurze T. 1974; Defibrination after brain – tissue destruction. A serious complication of head injury. New England Journal of Medicine 290: 1043.
    CrossrefPubMedGoogle Scholar
  • 47 Grant L. 1973. The sticking and emigration of white blood cells in inflammation. In: The Inflammatory Process. Academic Press; New York and London: 205.
    Google Scholar
  • 48 Gurewich V, Hutchinson E. 1971; Detection of intravascular coagulation by a serial-dilution protamine sulfate test. Annals of Internal Medicine 75: 895.
    CrossrefPubMedGoogle Scholar
  • 49 Haddy F. J, Scott J. B, Grega G. J. 1972; Effects of histamine on lymph protein concentration and flow in the dog fore limb. American Journal of Physiology 223: 1172.
    PubMedGoogle Scholar
  • 50 Harpel P, Bang N. U, Homburger F, Treger A. 1966; Plasminogen activator in mouse uterine fluid: Its suppresion by estradiol and progesterone. Proceedings of the Society for Experimental Biology and Medicine 22: 1192.
    PubMedGoogle Scholar
  • 51 Harpel P. C, Mosesson M. W. 1973; Degradation of human fibrinogen by plasma α2-macroglobulin-enzyme complexes. Journal of Clinical Investigation 52: 2175.
    CrossrefPubMedGoogle Scholar
  • 52 Hathaway W. E, Belhasen L. P, Hathaway H. S. 1965; Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood 26: 521.
    PubMedGoogle Scholar
  • 53 Hawiger J, Niewiarowski S, Gurewich V, Thomas D. P. 1970; Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. Journal of Laboratory Clinical Medicine 75: 93.
    PubMedGoogle Scholar
  • 54 Haynes F. 1932; Factors which influence the flow and protein content of subcutaneous lymph in the dog. II. The effect of certain substances which alter the capillary circulation. Journal of Physiology (London) 101: 612.
    PubMedGoogle Scholar
  • 55 Herold R, Straub P. W. 1973; In vivo role of factor XII (Hageman factor) in hypercoagulability and fibrinolysis. Journal of Laboratory Clinical Medicine 79: 397.
    PubMedGoogle Scholar
  • 56 Highsmith R. F, Rosenberg R. D. 1974; The inhibition of human plasmin by antithrombin-heparin cofactor. Journal of Biology and Chemistry 249: 4335.
    PubMedGoogle Scholar
  • 57 Hume M, Chan Y.-K. 1969. Discrimination between normals and patients with venous thrombosis based on blood tests. In: Thrombosis. (eds.) Sherry S, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C.: 566.
    Google Scholar
  • 58 Hume M, Sevitt S, Thomas D. P. 1970. Mechanisms of venous thrombosis. In: Venous Thrombosis and Pulmonary Embolism. Harvard University Press; Cambridge, Mass.: 58.
    Google Scholar
  • 59 Jofee S. N. 1975; The incidence of postoperative deep vein thrombosis. Thrombosis Research 7: 141.
    CrossrefPubMedGoogle Scholar
  • 60 Johnson J. F, Seegers W. H, Braden R. G. 1952; Plasma Acglobulin changes in placenta abruption. American Journal of Clinical Pathology 22: 322.
    CrossrefPubMedGoogle Scholar
  • 61 Kalousek F, Konigsberg W, Nemerson Y. 1975; Activation of factor IX by activated factor X: A link between the extrinsic and intrinsic coagulation systems. FEBS Letters 50: 382.
    CrossrefPubMedGoogle Scholar
  • 62 Kaplan A. P, Austen K. F. 1971; Prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor digestion with plasmin. Journal of Experimental Medicine 133: 696.
    CrossrefPubMedGoogle Scholar
  • 63 Kaplan A. P, Austen K. F. 1972; a The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivation. Journal of Experimental Medicine 136: 1378.
    CrossrefPubMedGoogle Scholar
  • 64 Kaplan A. P, Kay A. B, Austen K. F. 1972; b A prealbumin activator of kallikrein. III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. Journal of Experimental Medicine 135: 81.
    CrossrefPubMedGoogle Scholar
  • 65 Keller H. N, Sorkin E. 1968; Chemostaxis of leukocytes. Experientia 24: 641.
    CrossrefPubMedGoogle Scholar
  • 66 Kwaan H. C, Lo R, McFadzean A. J. S. 1957; On the production of plasma fibrinolytic activity within veins. Clinical Sciences 16: 241.
    PubMedGoogle Scholar
  • 67 Laake K, Osterud B. 1974; Activation of purified plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Thrombosis Research 5: 759.
    CrossrefPubMedGoogle Scholar
  • 68 Lahiri B, Talamo R. C, Mitchell B, Bagdasarían A, Colman R. W, Rusenberg R. 1976; Antithrombin III, an inhibitor of plasma kallikrein. Archives of Biochemistry and Biophysics 175: 137.
    PubMedGoogle Scholar
  • 69 Landerman N. S, Webster M. E, Becker E. L, Ratcliffe H. D. 1962; Heriditary angioneurotic edema. Journal of Allergy 33: 330.
    CrossrefPubMedGoogle Scholar
  • 70 Lasch H. G, Heene D. L, Huth K, Sandritter W. 1967; Pathophysiology clinical manifestations and therapy of consumption – coagulopathy (Verbrauchs-Koagulopathie). American Journal of Cardiology 20: 381.
    CrossrefPubMedGoogle Scholar
  • 71 Leary O. C, Hertig A. T. 1950; The pathogenesis of amniotic-fluid embolism. I. Possible placental factors — aberrant squamous cells in placentas. New England Journal of Medicine 243: 588.
    CrossrefPubMedGoogle Scholar
  • 72 Leavey R. A, Kahn S. B, Brodsky I. 1970; Disseminated intravascular coagulation, a complication of chemotherapy in acute myelomonocytic leukemia. Cancer 26: 142.
    CrossrefPubMedGoogle Scholar
  • 73 Lewis G. P. 1967; Intracellular enzymes in local lymph as a measure of cellular injury. Journal of Physiology (London) 191: 591.
    PubMedGoogle Scholar
  • 74 Lewis G. P. 1969; Changes in composition of rabbit hind limb lymph after injury. Journal of Physiology (London) 205: 619.
    CrossrefPubMedGoogle Scholar
  • 75 Lewis G. P. 1975; A lymphatic approach to tissue injury. New England Journal of Medicine 293: 287.
    CrossrefPubMedGoogle Scholar
  • 76 Lewis G. P, Wawretschek W. A. 1971; Effect of thermal injury on the kinin system in rabbit hind limb lymph. British Journal of Pharmacology 43: 127.
    CrossrefPubMedGoogle Scholar
  • 77 Lewis G. P, Winsey N. J. P. 1970; The action of pharmacologically active substances on the flow and composition of cat hind limb lymph. British Journal of Pharmacology 40: 446.
    CrossrefPubMedGoogle Scholar
  • 78 Liban E, Raz S. 1966; A clinicopathologic study of fourteen cases of amniotic fluid embolism. American Journal of Clinical Pathology 51: 477.
    PubMedGoogle Scholar
  • 79 Liu C. T. 1971; Traumatic shock: Evidence for chemical release from traumatized tissue in dogs. Aerospace Medicine 42: 403.
    PubMedGoogle Scholar
  • 80 Loosli C. G, Baker R. F. 1963; Acute experimental pneumococcal (Type I) pneumonia in the mouse: The migration of leukocytes from the pulmonary capillaries into the alveolar spaces as revealed by the electron microscope. Transactions of American Clinical Climatologic Association 74: 15.
    PubMedGoogle Scholar
  • 81 Lorentsen E, Eika C, Godal H. C. 1974; Coagulation studies in chronically bedridden patients. Acta Medica Scandinavia 195: 79.
    PubMedGoogle Scholar
  • 82 MacFArlane R. G, Biggs R. 1946; Observations on fibrinolysis. Spontaneous activity associated with surgical operations, trauma, etc. Lancet II: 862.
    PubMedGoogle Scholar
  • 83 Majno G, Palade G. E, Schoetl G. I. 1961; Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: A topographic study. Journal of Biophysical and Biochemical Cytology 11: 607.
    CrossrefPubMedGoogle Scholar
  • 84 Mandle R, Kaplan A. P. 1977 Hageman factor substrates. II. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation on Hageman factor proteolysis. Journal of Biological Chemistry. in press.
    PubMedGoogle Scholar
  • 85 Marciniak E, Farley C. H, DeSimone P. A. 1974; Familial thrombosis due to antithrombin III deficiency. Blood 43: 219.
    PubMedGoogle Scholar
  • 86 Marcus A. J, Zucker-Franklin D. 1964; Studies on subcellular platelet particles. Blood 23: 389.
    PubMedGoogle Scholar
  • 87 Margolis J. 1958; Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation. Journal of Physiology 144: 1.
    PubMedGoogle Scholar
  • 88 Marshall R, Esnouf M. P. 1968; The effect of Ancistrodon rhodostoma venom in the dog. Clinical Sciences 35: 251.
    PubMedGoogle Scholar
  • 89 Mayon-White R, Solandt O. M. 1941; A case of limb compression ending in uraemia. British Medical Journal 1: 434.
    CrossrefPubMedGoogle Scholar
  • 90 McCarell T. D, Drinker C. K. 1941; Cervical lymph production during histamine shock in the dog. American Journal of Pathology 133: 64.
    PubMedGoogle Scholar
  • 91 McConnell D. J, Loeb J. N. 1974; Kallikrein inhibitory capacity of α1-macroglobulin subunits. Proceedings of the Society for Experimental Biology and Medicine 147: 891.
    PubMedGoogle Scholar
  • 92 McKay D. G. 1965. In: Disseminated Intravascular Coagulation. An Intermediary Mechanism of Disease. Hoeber Medical Division, Harper and Roe; Newfork, Evanston and London: 359.
    Google Scholar
  • 93 McKay D. G, Muller-Berghaus G. 1967; Therapeutic implications of disseminated intravascular coagulation. American Journal of Cardiology 20: 392.
    CrossrefPubMedGoogle Scholar
  • 94 McKay D. G, Shapiro S. S. 1958; Alterations in the blood coagulation system induced by bacterial endotoxin. I. In vivo (generalized Shwartzman reaction). Journal of Experimental Medicine 107: 353.
    CrossrefPubMedGoogle Scholar
  • 95 McKenzie R, Pepper D. S, Kay A. B. 1975; The generation of chemotactic activity for human leukocytes by the action of plasmin on human fibrinogen. Thrombosis Research 6: 1.
    CrossrefPubMedGoogle Scholar
  • 96 Menton I. S, White R. W. B, Smith P. A, Dewar H. A. 1967; Diurinal variation of fibrinolytic activity and plasma-11-hydroxycorticosteroid levels. Lancet II: 531.
    PubMedGoogle Scholar
  • 97 Mersky C, Johnson A. J, Kleiner G. J, Wohl H. 1967; The defibrination syndrome: clinical features and laboratory diagnosis. British Journal of Haematology 13: 528.
    CrossrefPubMedGoogle Scholar
  • 98 Mersky G, Kleiner G. J, Johnson A. J. 1966; Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1.
    PubMedGoogle Scholar
  • 99 Minna J. D, Robboy S. J, Colman R. W. 1974. In: Disseminated Intravascular Coagulation in Man. Charles C. Thomas; Springfield, Ill.: 3.
    Google Scholar
  • 100 Mortiz A. R, Adelson L. 1971. Physical agents in causation of injury and disease. In: Pathology. (ed.) Anderson W. A. D. The C. V. Mosby Co.; St. Louis: 152.
    Google Scholar
  • 101 Mylon E, Winternitz M. D. 1946; The differentiation of potassium from other agents associated with the toxic effects of tourniquet shock. American Journal of Physiology 146: 254.
    PubMedGoogle Scholar
  • 102 Nemerson Y. 1976; Biological control of factor VII. Thrombosis and Haemostasis 35: 96.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 103 Nemerson Y, Pitlick F. A. 1970; Purification and characterization of the protein component of tissue factor. Biochemistry 9: 5100.
    CrossrefPubMedGoogle Scholar
  • 104 Netsky M. G, Leiter S. S. 1943; Capillary permeability to horse protein in burn shock. American Journal of Physiology 140: 1.
    PubMedGoogle Scholar
  • 105 Nicolaides A. N, Gordon-Smith I. 1975. In: Thromboembolism: Aetiology, Advances inprevention and Management. A rational approach to prevention. Medical and Technical Publishing Co. Ltd.; Lancester: 205.
    Google Scholar
  • 106 Nicolaides A. N, Kakkar V. V, Field E. S, Renney J. T. G. 1971; The origin of deep vein thrombosis: a venographic study. British Journal of Radiology 44: 653.
    CrossrefPubMedGoogle Scholar
  • 107 Niewiarowski S. 1973. Detection of fibrinogen derivatives in plasma and in serum and its significance in the diagnosis of intravascular coagulation and fibrinolysis. In: French Congress of Anaestheology. (Symposium on Fibrinolysis and Defibrination). Librairie Arnett; Paris: 67.
    Google Scholar
  • 108 Niewiarowski S, Bankowski E, Rogowicka R. 1965; Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin. Thrombosis et Diathesis Haemorrhagica 14: 387.
    PubMedGoogle Scholar
  • 109 Niewiarowski S, Kowalski E. 1958; Un nouvel anticoagulant derive du fibrinogene. Revue d’ Hematologie 13: 320.
    PubMedGoogle Scholar
  • 110 Niewiarowski S, Prou-Wartell O. 1959; Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombosis et Diathesis Haemorrhagica 3: 593.
    PubMedGoogle Scholar
  • 111 Niewiarowski S, Regoecz E, Mustard J. F. 1972; Platelet interaction with fibrinogen and fibrin: comparison of the interaction of platelets with that of fibroblasts, leukocytes and erythrocytes. Annals of the New York Academy of Sciences 201: 72.
    CrossrefPubMedGoogle Scholar
  • 112 Nusbacher J. 1964; Migratory venous thrombosis and cancer. New York State Journal of Medicine 64: 2166.
    PubMedGoogle Scholar
  • 113 Obata I. 1919; On the nature of eclampsia. Journal of Immunology 4: 111.
    PubMedGoogle Scholar
  • 114 Ogston D, Fullerton H. 1961; Changes in fibrinolytic activity produced by physical activity. Lancet II: 730.
    PubMedGoogle Scholar
  • 115 Østerud B, Rapaport S. I, Lavin K. K. 1977; Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood 49: 819.
    PubMedGoogle Scholar
  • 116 Owen Jr. C. A, Bowie E. J. W, Didisheim P, Thompson J. A, Spitell Jr. J. A. 1969. Factor VII and TGA types of hypercoagulabitility. In: Thrombosis. (eds.) Sherry S, Brinkhous K. M, Genton E, Stengle J. M. National Academy of Sciences; Washington, D. C.: 573.
    Google Scholar
  • 117 Page E. W, Fulton L. D, Glendening M. B. 1951; The cause of the blood coagulation defect following abruptio placentae. American Journal of Obstetrics and Gynecology 61: 1116.
    CrossrefPubMedGoogle Scholar
  • 118 Peterson E. P, Taylor H. B. 1970; Amniotic fluid embolism, an analysis of 40 cases. Obstetrics and Gynecology 35: 787.
    PubMedGoogle Scholar
  • 119 Phillips L. L. 1967; Alterations in the blood clotting system in disseminated intravascular coagulation. American Journal of Cardiology 20: 174.
    CrossrefPubMedGoogle Scholar
  • 120 Pizzo S. V, Schwartz M. L, Hill R. L, McKee P. A. 1972; Mechanism of Ancrod anticoagulation: A direct proteolytic effect on fibrin. Journal of Clinical Investigation 51: 2841.
    CrossrefPubMedGoogle Scholar
  • 121 Preston F. E, Malia R. G, Worn M. J, Blackburn E. K. 1973; Intravascular coagulation and E. coli septicemia. Journal of Clinical Pathology 26: 120.
    CrossrefPubMedGoogle Scholar
  • 122 Quick A. J. 1938; Normal antithrombin of blood and its relation to heparin. American Journal of Physiology 123: 712.
    PubMedGoogle Scholar
  • 123 Quick A. J, Hussey C. V, Harris J, Peters K. 1959; Effect of injecting thrombin intravenously. Federation Proceedings 18: 305.
    PubMedGoogle Scholar
  • 124 Radcliffe R, Bagdasarian R, Colman R. W, Nemerson Y. Activation of factor VII by Hageman factor fragments. Blood. in press.
    PubMedGoogle Scholar
  • 125 Ratnoff O. D. 1966. The biology and pathology of the initial stages of blood coagulation. In: Progress in Hematology. (eds.) Moore C. V, Brown E. Grune and Stratton; New York: 204.
    Google Scholar
  • 126 Ratnoff O. D, Busse R. J, Sheon R. P. 1968; The demise of John Hageman. New England Journal of Medicine 279: 760.
    CrossrefPubMedGoogle Scholar
  • 127 Ratnoff O. D, Davie E. W, Mallett D. L. 1961; Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. Journal of Clinical Investigation 40: 803.
    CrossrefPubMedGoogle Scholar
  • 128 Reichle F. A, Stewart G. J. 1973; A transmission and scanning electron microscopic study of luminal surfaces in Dacron and autogenous vein bypass in man and dog. Surgery 74: 945.
    PubMedGoogle Scholar
  • 129 Reid D. E, Weiner A. E, Roby C. C. 1953; Maternal afibrinogenomia associated with long standing intrauterine fetal death. American Journal of Obstetrics and Gynecology 66: 500.
    CrossrefPubMedGoogle Scholar
  • 130 Revak S. D, Cochrane C. G, Johnston A. R, Hugli T. E. 1974; Structural changes accompanying enzymatic activation of human Hageman factor. Journal of Clinical Investigation 54: 619.
    CrossrefPubMedGoogle Scholar
  • 131 Rimon A, Shamash Y, Shaprio B. 1966; The plasmin inhibitor of human plasma IV. Its action on plasmin, trypsin, chymotrypsin and thrombin. Journal of Biological Chemistry 241: 5102.
    PubMedGoogle Scholar
  • 132 Ritchie W. G. W, Lynch P. R, Stewart G. J. 1974; The effect of contrast media on normal and inflammed canine venins: A scanning and transmission electron microscopic study. Investigative Radiology 9: 444.
    CrossrefPubMedGoogle Scholar
  • 133 Robboy S. J, Colman R. W, Minna J. D. 1972; Fibrinolysis versus disseminated intravascular coagulation (DIC): analysis of twenty six cases. Human Pathology 3: 327.
    CrossrefPubMedGoogle Scholar
  • 134 Robboy S. J, Mihm M. C, Colman R. W, Minna J. D. 1973; The skin in disseminated intravascular coagulation (DIC): prospective analysis of 36 cases. British Journal of Dermatology 88: 221.
    CrossrefPubMedGoogle Scholar
  • 135 Rodriguez-Erdman F. 1965; Bleeding due to increased intravascular blood coagulation: hemorrhagic syndromes caused by consumption of blood-clotting factors (consumption coagulopathies). New England Journal of Medicine 237: 1370.
    PubMedGoogle Scholar
  • 136 Rosenberg R. D. 1975; Actions and interaction of antithrombin and heparin. New England Journal of Medicine 292: 146.
    CrossrefPubMedGoogle Scholar
  • 137 Ruckley C. V, Das P. C, Leitch A. G, Donaldson A. A, Copland W. A, Redpath A. T, Scott P, Cash J. D. 1970; Serum fibrin/fibrinogen degradation products associated with postoperative pulmonary embolus and venous thrombosis. British Medical Journal 4: 395.
    CrossrefPubMedGoogle Scholar
  • 138 Saito H, Ratnoff O. D, Donaldson V. H. 1974; Defective activation of clotting, fibrinolytic and permeability — enhancing systems in human Fletcher trait plasma. Circulation Research 34: 641.
    CrossrefPubMedGoogle Scholar
  • 139 Saito H, Ratnoff O. D, Waldmann R, Abraham J. P. 1975; Fitzgerald trait: deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface – mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability. Journal of Clinical Investigation 55: 1082.
    CrossrefPubMedGoogle Scholar
  • 140 Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. 1960; Studies on the thrombolytic activity of human plasma. Journal of Clinical Investigations 39: 426.
    CrossrefPubMedGoogle Scholar
  • 141 Schiffman S, Lee P. 1974; Preparation, characterization and activation of a highly purified factor XI: Evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. British Journal of Haematology 27: 101.
    CrossrefPubMedGoogle Scholar
  • 142 Schiffman S, Rimon A, Rapaport S. I. 1977; Factor XI and platelets: Evidence thatplatelets contain only minimal factor XI activity and antigen. British Journal of Haematology 35: 429.
    CrossrefPubMedGoogle Scholar
  • 143 Schneider C. L. 1947; The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. American Journal of Physiology 149: 123.
    PubMedGoogle Scholar
  • 144 Schneider C. L. 1951; Fibrin embolism (Disseminated intravascular coagulation) with defibrination as one of the end results of placenta abruption. Surgery, Gynecology and Obstetrics 92: 27.
    PubMedGoogle Scholar
  • 145 Schreiber A. D, Kaplan A. P, Austen K. F. 1973; Inhibition by Cl – INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin generation. Journal of Clinical Investigation 52: 1402.
    CrossrefPubMedGoogle Scholar
  • 146 Seegers W. H, Marciniak E. 1962; Inhibition of autoprothrombin C activity with plasma. Nature 193: 1188.
    PubMedGoogle Scholar
  • 147 Seegers W. H, Schneider C. L. 1951. The nature of the blood coagulation mechanism and its relationship to some unsolved problems in obstetrics and gynecology. Fourth International and American Congress on Obstetrics and Gynecology. C. V. Mosby Co.; St. Louis: 469.
    Google Scholar
  • 148 Seegers W. H, Warner E. D, Brinkhous K. M, Smith H. P. 1942; Heparin and antithrombotic activity of plasma. Science 96: 300.
    CrossrefPubMedGoogle Scholar
  • 149 Sevitt S. 1958; Early and delayed edema and increase in capillary permeability after burns of the skin. Journal of Pathology and Bacteriology 75: 27.
    CrossrefPubMedGoogle Scholar
  • 150 Sevitt S, Gallagher N. C. 1961; Venous thrombosis and pulmonary embolism: A clinicopathological study in injured and burned patients. British Journal of Surgery 48: 475.
    CrossrefPubMedGoogle Scholar
  • 151 Sherry S, Fletcher A. P, Alkjaersig N. 1959; Fibrinolysis and fibrinolytic activity in man. Physiology Review 39: 343.
    CrossrefPubMedGoogle Scholar
  • 152 Shoemaker W. C, Lim L, Boyd D. R, Corley R. S, Reinhard J. M, Dreiling D. A, Kark A. E. 1971; Sequential hemodynamic events after trauma to the unanesthetized patients. Surgery, Gynecology and Obstetrics 132: 651.
    PubMedGoogle Scholar
  • 153 Short A. R. 1914; The nature of surgical Shock. British Journal of Surgery 1: 114.
    PubMedGoogle Scholar
  • 154 Soltay M. J, Movat H. Z, Ozge-Anwar A.H. 1971; The kinin system and human plasma V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa). Proceedings of the Society for Experimental Biology and Medicine 138: 952.
    PubMedGoogle Scholar
  • 155 Sorkin E, Stecher V. J, Borel J. F. 1970; Chemotaxis of leukocytes and inflammation. Series Haematologica 3: 131.
    PubMedGoogle Scholar
  • 156 Stecher V. J, Sorkin E. 1972; The chemotactic activity of fibrin lysis products. International Archives of Allergy 43: 879.
    CrossrefPubMedGoogle Scholar
  • 157 Stefanini M, Campbell E. W. 1954; Isolation and purification of platelet thromboplastic factor; its physicochemical and biologic properties in vitro and in vivo. Hematology Review 9: 576.
    PubMedGoogle Scholar
  • 158 Stewart G. J, Lynch P. R. 1977; a Independence of intravascular generation of fibrin monomer and fibrin deposition on canine jugular veins. Thrombosis Research 10: 147.
    CrossrefPubMedGoogle Scholar
  • 159 Stewart G. J, Lynch P. R, Reichle F. A, Ritchie W. G. M, Smith A, Schaub R. G. 1977; a The adhesion of leukocytes, erythrocytes and noncellular material to the luminal surface of natural and artificial blood vessels in vivo. Annals of New York Academy of Sciences 283: 179.
    CrossrefPubMedGoogle Scholar
  • 160 Stewart G. J, Ritchie W. G. M, Lynch P. R. 1973. A scanning and transmission electron microscopic study of canine jugular veins. Scanning electron microscopy (Part III). Proceedings of the workshop on Scanning Electron Microscopy in Pathology. ITT Research Institute; Chicago, Ill.: 463.
    Google Scholar
  • 161 Stewart G. J, Ritchie W. G. M, Lynch P. R. 1974; Venous damage produced by massive sticking and emigration of leukocytes. American Journal of Pathology 74: 507.
    PubMedGoogle Scholar
  • 162 Surgenor D. M, Wallach D. F. H. 1961. Biophysical aspects of platelet reaction mechanisms in clotting. (eds.) Johnson S. A. S. N, Monto R. W, Reback J. W, Horn Jr. R. C. In: Blood platelets. Little, Brown and Co.; Boston: 289.
    Google Scholar
  • 163 Thomas D. P, Niewiarowski S, Meyers A. P, Block K. J, Colman R. W. 1970; A comparative study of four methods for detecting fibrinogen degradation products from patients with various disease. New England Journal of Medicine 283: 663.
    CrossrefPubMedGoogle Scholar
  • 164 Van Creveld S, Paulssen M. M. P. 1953; A form of hemorrhagic diathesis characterized by the lack of the third clotting factor, normally present in blood-platelets (thrombopathia haemophilica). Annals of Paediatrics 181: 193.
    PubMedGoogle Scholar
  • 165 Vecchione J, Zucker M. B. 1975; Procoagulant activity of platelets in recalcified plasma. British Journal of Haematology 31: 423.
    CrossrefPubMedGoogle Scholar
  • 166 Vennerod A. M, Laake K. 1975; Inhibition of purified plasma kallikrein by antithrombin III and heparin. Thrombosis Research 7: 223.
    CrossrefPubMedGoogle Scholar
  • 167 Verstraete M, Vermylen L, Vermylen C, Vandenbroucke J. 1965; Excessive consumption of blood coagulation components as cause of hemorrhagic diathesis. American Journal of Medicine 38: 899.
    CrossrefPubMedGoogle Scholar
  • 168 Virchow R. 1860. Metastatical dyscrasiae. Lecture in Cellular Pathology. Churchill: 196.
    Google Scholar
  • 169 Von Kaulla E, Droegemueller W, Aoki N, von Kaulla K. N. 1971; Antithrombin 3 depression and thrombin generation acceleration in women taking oral contraceptives. American Journal of Obstetrics and Gynecology 109: 868.
    CrossrefPubMedGoogle Scholar
  • 170 Walsh P. N. 1972; a The role of platelets in the contact phase of blood coagulation. British Journal of Haematology 22: 237.
    CrossrefPubMedGoogle Scholar
  • 171 Walsh P. N. 1972; b The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requirin factor XII. British Journal of Haematology 22: 393.
    CrossrefPubMedGoogle Scholar
  • 172 Walsh P. N, Lipscomb M. S. 1976; Comparison of the coagulant activities of platelets and phospholipids. British Journal of Haematology 33: 9.
    CrossrefPubMedGoogle Scholar
  • 173 Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E. S, Sherry S. 1976; The relationship of platelet coagulant activities to venous thrombosis following hip surgery. British Journal of Haematology 32: 423.
    PubMedGoogle Scholar
  • 174 Ward P. A. 1967; A plasmin-split fragment of C3 as a new chemotactic factor. Journal of Experimental Medicine 126: 189.
    CrossrefPubMedGoogle Scholar
  • 175 Weiss A. S, Gallin J. I, Kaplan A. P. 1974; Fletcher factor deficiency. A diminshed rate of Hageman factor activation caused by absence of prekallikrein with abnomalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. Journal of Clinical Investigation 53: 622.
    CrossrefPubMedGoogle Scholar
  • 176 Wessler S. 1952; Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. Journal of Clinical Investigation 31: 1011.
    CrossrefPubMedGoogle Scholar
  • 177 Wessler R. 1955; Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. Journal of Clinical Investigation 34: 647.
    CrossrefPubMedGoogle Scholar
  • 178 Wessler S, Reimer L, Freiman D. G, Reimer S. M, Lortzman M. 1959; Serum-induced thrombosis. Studies of its introduction and evolution under controlled conditions in vivo. Circulation 20: 864.
    CrossrefPubMedGoogle Scholar
  • 179 Wessler S, Yin E. T. 1968; The experimental hypercoagulable state induced by Factor X: comparison of the non-activated and activated forms. Journal of Laboratory Clinical Medicine 72: 256.
    PubMedGoogle Scholar
  • 180 Wilner G. D, Nossel H. L, Leroy E. C. 1968; Activation of Hageman factor by collagen. Journal of Clinical Investigation 47: 2608.
    CrossrefPubMedGoogle Scholar
  • 181 Wood E. H, Prentice C. R. M, McNicol G. P. 1972; Association of fibrinogen-fibrin related antigen (F. R.-antigen) with postoperative deep vein thrombosis and systemic complication. Lancet I: 166.
    PubMedGoogle Scholar
  • 182 Wuepper K. D. 1972. Biochemistry and biology of components of the plasmin kinin system. In: Inflammation, Mechanism and Control. (eds.) Lepow I. H, Ward P. A. Academic Press; New York: 93.
    Google Scholar
  • 183 Wuepper K. D, Miller D. R, Lacombe M. J. 1975; Flaujeac trait. Deficiency of human plasma kininogen. Journal of Clinical Investigation 56: 1663.
    CrossrefPubMedGoogle Scholar
  • 184 Yin T. E, Wessler S, Stoll P. J. 1971; Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biology and Chemistry 246: 3712.
    PubMedGoogle Scholar
  • 185 Zachariae H, Malmquest J, Oates J. A, Pettinger W. 1976; Studies on the mechanism of kinin formation in inflammation. Journal of Physiology 190: 81.
    PubMedGoogle Scholar
  • 186 Zuck T. F, Bergin J. J. 1973; Thrombotic predispostion associated with oral contraceptives. Obstetrics and Gynecology 41: 427.
    PubMedGoogle Scholar
  • 187 Zuck T. F, Bergin J. J, Raymond J. M. 1971; Implications of depressed antithrombin III activity associated with oral contraceptives. Surgery, Gynecology and Obstetrics 133: 609.
    PubMedGoogle Scholar